Liver Institute of Virginia Education, Research and Treatment for Patients with Liver Disease IVer Bon Secours Health System WHY CHOOSE TELAPREVIR Mitchell.

Slides:



Advertisements
Similar presentations
Future Directions in HCV Therapy Eric Lawitz, MD, AGAF,CPI Medical Director, The Texas Liver Institute Clinical Professor of Medicine University of Texas.
Advertisements

Optimal therapy in genotype 2 and 3 patients Antonio Craxì Liver & GI Unit, Di.Bi.M.I.S., University of Palermo, Italy
Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.
Protease and Polymerase Inhibitors for the Treatment of Hepatitis C
WHAT FUTURE FOR RIBAVIRIN? Mitchell L Shiffman, MD Chief, Hepatology Section Medical Director, Liver Transplant Program Virginia Commonwealth University.
Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.
Hepatitis web study H EPATITIS W EB S TUDY Use of & Telaprevir (Incivek) in the Treatment of Chronic Hepatitis C Virus Presentation Prepared by: David.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in GT 1-6 (Flat versus Weight-Based Ribavirin Dosing) WINR Study Phase 3 Treatment.
Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 TURQUOISE-II Phase 3 Treatment.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Jacobson IM, et al.
Hepatitis web study Hepatitis web study PEG alfa-2a + RBV versus PEG alfa-2a versus INF + RBV APRICOT STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV IDEAL STUDY Phase 3, Treatment Naïve Treatment Naïve,
Hepatitis web study Hepatitis web study Duration and Dose Finding Peginterferon alfa-2a + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Randomized study.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3 Phase 3 Treatment Naïve, Chronic HCV Mangia A, et.
Hepatitis web study Hepatitis web study Peginterferon alfa -2a+/- Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV.
Compensated Cirrhosis
Hepatitis web study Hepatitis web study WINR Study Flat versus Weight-Based Ribavirin Dosing Phase 3 Treatment Naïve, Chronic HCV Jacobson IM, et. al.
Hepatitis C Genotype 3 Paris 2012 Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.
Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a +/- Ribavirin for Chronic HCV Phase 3 Treatment Naïve, Chronic HCV Fried MW, et. al. N Engl.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin Paul Y Kwo, MD Professor of Medicine Medical Director,
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France.
CURRY  Design Open-label CURRY Study: SOF + RBV for HCV with liver cancer before transplantation ≥ 18 years Chronic HCV infection Any genotype HCV RNA.
Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study Phase 3 Treatment-Naïve and Treatment-Experienced Nelson DR,
How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.
HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON.
Response Guided Vs.Response Unguided Therapy K.Rajender Reddy M.D Professor of Medicine University of Pennsylvania Philadelphia, USA.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Ribavirin (Copegus, Rebetol, Ribasphere) Prepared by: David Spach, MD and H. Nina Kim,
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites Phase 3 Treatment Naïve, Chronic HCV Muir AJ,
Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.
ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.
Lead in – or NOT? Graham R Foster Professor of Hepatology Queen Marys University of London.
Hepatitis C Nonresponders
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.
Triple Therapy Today Phase III Results in G1 Relapsers and Non Responders – Telaprevir 5 th Paris Hepatitis Conference Paris, 30. January 2012 Stefan Zeuzem.
 Design  Objective –Difference in SVR ≥ 40% between the 2 groups, 99% power SOF + RBV Placebo Randomisation 3 : 1* Double blind HCV infection Genotype.
Dore G. J Hepatol 2016; 64:19-28 MALACHITE TVR + PEG-IFN + RBV Randomisation Open-label years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I)
Poordad F. NEJM 2014;368: D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Telaprevir (Incivek) Prepared by: David Spach, MD & H. Nina Kim, MD Last Updated: February.
 Design Open-label years Chronic HCV infection Genotype 1 HCV RNA > 10,000 IU/mL HIV co-infection Stable ART* with HIV RNA < 50 c/mL ≥ 24 weeks.
36 year old HCV+ woman, Risk factor: occasional IVDU 15 years ago First treatment with PEG-IFN/RBV in 2002 –only qualitative PCR available : positive at.
Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Naïve GT 1-6 POLARIS-2
Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
No cirrhosis or compensated cirrhosis** No HBV or HIV co-infection
Boceprevir in Treatment Naive SPRINT-2
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study
Volume 59, Issue 4, Pages (October 2013)
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
ION-3 Study: LDV/SOF + RBV for naïve genotype 1
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
Volume 142, Issue 6, Pages (May 2012)
Telaprevir in Treatment Experienced GT-1 PROVE3
Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.
Presentation transcript:

Liver Institute of Virginia Education, Research and Treatment for Patients with Liver Disease IVer Bon Secours Health System WHY CHOOSE TELAPREVIR Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA

IVer TELAPREVIR TREATMENT NAÏVE AND RELAPSE HCV RNAUD RVR Telaprevir PEGINF Ribavirin PEGINF Ribavirin No RVR PEGINF-RBV Log HCV< 3 UD Stop Rule>3 + Week ML Shiffman, R Estaban Liver Intl 2012; 32 (suppl 1):54-60.

IVer TELAPREVIR NON-RESPONSE AND CIRRHOSIS RVR HCV RNA Telaprevir PEGINF Ribavirin No RVR PEGINF-RBV Log HCV< 3 UD Stop Rule>3 + Week ML Shiffman, R Estaban Liver Intl 2012; 32 (suppl 1):54-60.

IVer SVR RATES VERY COMPARABLE BoceprevirTelaprevir Treatment Naïve: eRVR Delayed response % with eRVR 96% 66-75% 56% 89-92% 64% 58-60% Retreatment: Relapse Partial response Null response INF sensitive (lead-in) INF insensitive (lead-in) 69-75% 40-52% NA 73-79% 33-34% 84-88% 56-61% 31-33% NA

IVer SVR RATES VERY COMPARABLE BoceprevirTelaprevir Treatment Naïve: eRVR Delayed response % with eRVR 96% 66-75% 56% 89-92% 64% 58-60% Retreatment: Relapse Partial response Null response INF sensitive (lead-in) INF insensitive (lead-in) 69-75% 40-52% NA 73-79% 33-34% 84-88% 56-61% 31-33% NA

IVer SVR RATES VERY COMPARABLE BoceprevirTelaprevir Treatment Naïve: eRVR Delayed response % with eRVR 96% 66-75% 56% 89-92% 64% 58-60% Retreatment: Relapse Partial response Null response INF sensitive (lead-in) INF insensitive (lead-in) 69-75% 40-52% NA 73-79% 33-34% 84-88% 56-61% 31-33% NA

IVer TELAPREVIR WHY CHOOSE THIS REGIMEN? It is just an easier treatment regimen

IVer TELAPREVIR ITS JUST EASIER All three medications are started at the same time All patients get 12 weeks of telaprevir Treatment naïve Prior relapse Prior non-response Cirrhosis

IVer TELAPREVIR ITS JUST EASIER If you have to stop telaprevir at week 8 for adverse events the SVR is only marginally reduced. 50% 54% Telaprevir PEGIFN-2a Ribavirin If NO eRVR: PEGINF + Ribavirin If eRVR: PEGINF + Ribavirin Telaprevir PEGIFN-2a Ribavirin % 89% Week of TPV Weeks 0 8 IM Jacobson et al. N Engl J Med 2011; 364:

IVer TELAPREVIR ITS JUST EASIER Only 2 treatment durations Treatment naïve and prior relapsers: 24 weeks if achieve extended rapid response 48 weeks with delayed response Prior non-response and cirrhosis 48 weeks

IVer TELAPREVIR ITS JUST EASIER 60% achieve eRVR. Treated for 24 weeks 21% have delayed response. Treated 48 weeks. 81% of patients become HCV RNA undetectable during treatment

IVer TELAPREVIR ITS JUST EASIER Smaller pill burden 2 capsules TID = 6/day Randomized controlled trial suggests telaprevir can be dosed 3 capsules BID without impacting SVR = P Marcellin et al. Gastroenterol 2011; 140:

IVer TELAPREVIR ITS JUST EASIER Stop rules at weeks 4 and 12. Allows resistant virus to be recognized earlier. Resistance monitoring uses the same cutt-off. Week 4 >Log 3 Week 12 >Log Week 24 negative

IVer TELAPREVIR NEGATIVE FEATURES Side effects of therapy Side effects of peginterferon and ribavirin Side effects of telaprevir Anemia Rash GI symptoms

IVer RASH UNIQUE TO TELAPREVIR Appears in over half of patients treated with telaprevir Typically appears during first 4 weeks of treatment Worsens progressively during treatment Most patients never reach stage 3-4 If severe, can stop telaprevir a few weeks early The decline in SVR is minimal even in patients with delayed virologic response

IVer TELAPREVIR GRADE 2 RASH

IVer TELAPREVIR GRADE 3 RASH

IVer TELAPREVIR GRADE 4 RASH

IVer TELAPREVIR SIDE EFFCTS GI toxicity: Nausea Vomiting Diarrhea Anal-rectal burning

IVer TELAPREVIR SUMMARY To treat HCV with Incevik Is not a trick. Just start it with PEG and Riba together. Treat for 12 weeks and see it get better. If negative at week 4. Its virtually a cure. Continue PEG and riba for sure. Till week 24. And then dash straight through the door.

IVer TELAPREVIR SUMMARY However, If the response is delayed. Do not be dismayed. For if less than a thousand by month 3. A cure can still be. Adhere to the stop rules at 4 and 12 weeks. This is important and so do not cheat. And you will see. This rule will keep you mutant free.

IVer TELAPREVIR SUMMARY AEs include rash, anemia and a sore bum. This is not fun. This make patients glum. And their physicians run. And so my friends, When treating with telaprevir there is no reason to quiver. Because its dam good at getting HCV Out of the liver.